TSOI Therapeutic Solutions International Inc.

Therapeutic Solutions International Reports its NanoStilbeneâ„¢ Nutraceutical Product Enhances Efficacy of FDA Cleared Cancer Immunotherapy in Animal Model of Cancer

Therapeutic Solutions International Reports its NanoStilbene™ Nutraceutical Product Enhances Efficacy of FDA Cleared Cancer Immunotherapy in Animal Model of Cancer

New Data Supports Development of Patented Formulation of Blueberry Extract Pterostilbene as an Adjuvant to Immuno-Oncology Treatments

OCEANSIDE, Calif., July 22, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Therapeutics Solutions International, Inc. () reported today positive animal data demonstrating synergy between its commercially available NanoStilbene™ nutraceutical product [1] together with anti-CTLA4 antibody, which is the mouse equivalent of Ipilimumab (Yervoy®), an FDA cleared immunotherapeutic which belongs to the family of drugs called "checkpoint inhibitors".  The new data supports the possibility that NanoStilbene™, a proprietary formulation of pterostilbene [2], may increase effectiveness of drugs that activate the immune system to kill cancer.

"The current set of animal experiments demonstrate not only that NanoStilbene™ enhances the ability of the CTLA-4 antibody to reduce tumor size, but also that NanoStilbene™ augments the number of lymphocytes entering the tumor.  This data, together with previous publications that pterostilbene itself suppresses a wide variety of tumors, support the possible development of our nutraceutical as an adjuvant to numerous immunotherapies," said Thomas Ichim, Ph.D., Board Member of TSOI and coinventor on the Company's patents.

Numerous independent laboratories have published in the peer reviewed literature that pterostilbene decreases the growth of prostate cancer [3], breast cancer [4], glioma [5], liver cancer [6], esophageal cancer [7], and melanoma [8].  The advantage of NanoStilbene™ as compared to pterostilbene capsules, which are widely available, is that the proprietary nanoformulation allows substantially higher concentrations of pterostilbene to reach the cancer cells.

"We at Therapeutic Solutions International are focused on a Science First approach to development of all of our products.  The new data disclosed today further supports our existing body of knowledge and patent filings which expand on our issued patent # 9,682,047, which covers utilization of pterostilbene with other immunotherapies," said Timothy Dixon, President and CEO of the Company. "We plan to expand our current studies in several areas, including exploring the effects of NanoStilbene™ on adoptive cellular immunotherapy and CAR-T cells."

[1]

[2]

[3] Dhar et al. Oncotarget. 2015 Sep 29;6(29):27214-26.

[4] Wakimoto et al. Differential Anticancer Activity of Pterostilbene Against Three Subtypes of Human Breast Cancer Cells. Anticancer Res. 2017 Nov;37(11):6153-6159.

[5] Huynh et al. Pterostilbene suppressed irradiation-resistant glioma stem cells by modulating GRP78/miR-205 axis. J Nutr Biochem. 2015 May;26(5):466-75.

[6] Qian et al. Pterostilbene inhibits MTA1/HDAC1 complex leading to PTEN acetylation in hepatocellular carcinoma. Biomed Pharmacother. 2018 May;101:852-859.

[7] Feng et al. Pterostilbene Inhibits the Growth of Human Esophageal Cancer Cells by Regulating Endoplasmic Reticulum Stress. Cell Physiol Biochem. 2016;38(3):1226-44.

[8] Benlloch et al. Pterostilbene Decreases the Antioxidant Defenses of Aggressive Cancer Cells In Vivo: A Physiological Glucocorticoids- and Nrf2-Dependent Mechanism. Antioxid Redox Signal. 2016 Jun 10;24(17):974-90.

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is and e-commerce at

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

CONTACT INFORMATION

Therapeutic Solutions International, Inc.

EN
22/07/2019

Underlying

Reports on Therapeutic Solutions International Inc.

 PRESS RELEASE

Therapeutic Solutions International Successfully Treats “No Option” Pa...

OCEANSIDE, Calif.--(BUSINESS WIRE)-- Therapeutic Solutions International (TSOI) announced today successful treatment of 15 recent patients under the Right to Try Law with the Company’s universal donor JadiCell™ adult stem cell product. All patients displayed no adverse events and demonstrated subjective and objective levels of improvement. There were 12 COVID-19 patients who underwent a profound recovery despite advanced stage of disease, while the retired Navy SEAL that was previously publicly disclosed1 along with two other retired SEALS, had a significant decrease in biomarkers associated ...

 PRESS RELEASE

Therapeutic Solutions International Reports NanoStilbeneâ„¢ Protects t...

Therapeutic Solutions International Reports NanoStilbene™ Protects the Immune System from Cancer Chemotherapy Newly Discovered Properties of NanoStilbene Potentially Allows Company to Address $3.9 Billion Chemotherapy Induced Neutropenia Market OCEANSIDE, Calif., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Therapeutics Solutions International, Inc., () announced today new data and the filing of a patent application covering the ability of NanoStilbene™ [1] and its active ingredient, pterostilbene, at accelerating recovery of blood cells after treatment with chemotherapy.  Neutropenia is an...

 PRESS RELEASE

Feng Lin, MD, Ph.D., Joins Therapeutic Solutions International as Chie...

Feng Lin, MD, Ph.D., Joins Therapeutic Solutions International as Chief Scientific Officer Immuno-Oncology Nutraceutical Company Positions Itself for Expansion into FDA OCEANSIDE, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Therapeutics Solutions International, Inc., () announced today the recruitment of Feng Lin, MD, Ph.D., as Chief Scientific Officer.  Dr. Lin has a stellar track record of drug development in the area of immunology and immuno-oncology having worked with the public company Inovio Pharmaceuticals, where he developed technologies for gene delivery an...

 PRESS RELEASE

Therapeutic Solutions International Inc. Reports Revenues Up 850% for ...

Therapeutic Solutions International Inc. Reports Revenues Up 850% for Q2 OCEANSIDE, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- via NetworkWire - Therapeutics Solutions International Inc. (OTC: TSOI) today reports that its second-quarter 2019 revenues increased 850%, as compared to the same period in 2018.  These increases were due primarily to the commercialization of NanoStilbene™ following the completion of clinical program that included a pharmacokinetic trial and a pilot cancer study in advanced cancer patients using 300mg of nanoparticle pterostilbene. As , results of this clinical...

 PRESS RELEASE

Therapeutic Solutions International Announces Positive Clinical Data U...

Therapeutic Solutions International Announces Positive Clinical Data Using NanoStilbene™ to Stimulate Immune System in Advanced Cancer Patients Company Submits Results of Clinical Trial for Publication in Peer Reviewed Medical Journal OCEANSIDE, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Therapeutics Solutions International, Inc., () announced today positive results from a pilot clinical trial in advanced cancer patients which have been submitted as a scientific manuscript to a peer reviewed medical journal.  In the manuscript, 12 advanced cancer patients were treated...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch